Dupont's Sustiva
Executive Summary
Anti-HIV non-nucleoside reverse transcriptase inhibitor efavirenz is understood to be tentatively scheduled for review by FDA's Anti-Viral Drugs Advisory Committee Oct. 5. DuPont Merck (now DuPont Pharmaceuticals) submitted the NDA June 10. Glaxo Wellcome's nucleoside analog Ziagen (abacavir) could also be added to the agenda if FDA decides that the drug merits advisory committee review